These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 29398150)

  • 21. Prognostic factors affecting the risk of thoracic progression in extensive-stage small cell lung cancer.
    Fukui T; Itabashi M; Ishihara M; Hiyoshi Y; Kasajima M; Igawa S; Sasaki J; Masuda N
    BMC Cancer; 2016 Mar; 16():197. PubMed ID: 26955807
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum albumin and derived neutrophil-to-lymphocyte ratio are potential predictive biomarkers for immune checkpoint inhibitors in small cell lung cancer.
    Kuang Z; Miao J; Zhang X
    Front Immunol; 2024; 15():1327449. PubMed ID: 38911864
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as prognostic markers in patients with extensive-stage small cell lung cancer treated with atezolizumab in combination with chemotherapy.
    Kutlu Y; Aydin SG; Bilici A; Oven BB; Olmez OF; Acikgoz O; Hamdard J
    Medicine (Baltimore); 2023 Apr; 102(15):e33432. PubMed ID: 37058061
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
    Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
    Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pretreatment Immune Parameters Predict for Overall Survival and Toxicity in Early-Stage Non-Small-Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy.
    Shaverdian N; Veruttipong D; Wang J; Schaue D; Kupelian P; Lee P
    Clin Lung Cancer; 2016 Jan; 17(1):39-46. PubMed ID: 26372098
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic significance of pretreatment neutrophil-to-lymphocyte ratio in older patients with metastatic cancer.
    Chen KH; Tsang NM; Chou WC; Tai SF; Liu SC; Lei KF; Chang KP; Chuang WC; Pai PC
    J Geriatr Oncol; 2019 Sep; 10(5):757-762. PubMed ID: 31085137
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The prognostic role of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in patients with stage III non-small cell lung cancer treated with concurrent chemoradiotherapy.
    Yılmaz U; Ozdemir O; Batum O; Ermin S
    Indian J Cancer; 2018; 55(3):276-281. PubMed ID: 30693894
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Role of Neutrophil-Lymphocyte Ratio, Platelet-Lymphocyte Ratio, and Platelets in the Prognosis of Metastatic Renal Cell Carcinoma.
    Huszno J; Kolosza Z; Mrochem-Kwarciak J; Rutkowski T; Skladowski K
    Oncology; 2019; 97(1):7-17. PubMed ID: 31048577
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor mutational burden adjusted by neutrophil-to-lymphocyte ratio serves as a potential biomarker for atezolizumab-treated patients with extensive stage small cell lung cancer.
    Zhang C; Huo Y; Shang X; Zhang T; Tang N; Wang H
    Respir Res; 2024 Jun; 25(1):253. PubMed ID: 38902698
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic value of pretreatment inflammatory biomarkers in advanced lung adenocarcinoma patients receiving first-line pemetrexed/platinum doublet.
    Xiong Y; Zhao N; Zheng Y; Wang J; Wei F; Ren X
    Tumour Biol; 2017 Jun; 39(6):1010428317701639. PubMed ID: 28618954
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pretreatment Neutrophil to Lymphocyte Ratio Is Associated with Poor Survival in Patients with Stage I-III Non-Small Cell Lung Cancer.
    Wang J; Kalhor N; Hu J; Wang B; Chu H; Zhang B; Guan Y; Wu Y
    PLoS One; 2016; 11(10):e0163397. PubMed ID: 27695079
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic value of pretreatment procalcitonin and neutrophil-lymphocyte ratio in extensive-stage small-cell lung cancer.
    Chen D; Xu J; Zhao Y; Han B; Zhong R
    Cancer Biol Ther; 2024 Dec; 25(1):2331273. PubMed ID: 38536706
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High Systemic Immune-Inflammation Index (SII) Represents an Unfavorable Prognostic Factor for Small Cell Lung Cancer Treated with Etoposide and Platinum-Based Chemotherapy.
    Wang C; Jin S; Xu S; Cao S
    Lung; 2020 Apr; 198(2):405-414. PubMed ID: 32016563
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic significance of pretreatment laboratory parameters in combined small-cell lung cancer.
    Wang X; Jiang R; Li K
    Cell Biochem Biophys; 2014 Jul; 69(3):633-40. PubMed ID: 24554485
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neutrophil-lymphocyte and platelet-lymphocyte ratios as prognostic factors after stereotactic radiation therapy for early-stage non-small-cell lung cancer.
    Cannon NA; Meyer J; Iyengar P; Ahn C; Westover KD; Choy H; Timmerman R
    J Thorac Oncol; 2015 Feb; 10(2):280-5. PubMed ID: 25299234
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neutrophil to lymphocyte ratio associated with prognosis of lung cancer.
    Bar-Ad V; Palmer J; Li L; Lai Y; Lu B; Myers RE; Ye Z; Axelrod R; Johnson JM; Werner-Wasik M; Cowan SW; Evans NR; Hehn BT; Solomides CC; Wang C
    Clin Transl Oncol; 2017 Jun; 19(6):711-717. PubMed ID: 27909873
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PIV and PILE Score at Baseline Predict Clinical Outcome of Anti-PD-1/PD-L1 Inhibitor Combined With Chemotherapy in Extensive-Stage Small Cell Lung Cancer Patients.
    Zeng R; Liu F; Fang C; Yang J; Luo L; Yue P; Gao B; Dong Y; Xiang Y
    Front Immunol; 2021; 12():724443. PubMed ID: 34777341
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neuron-specific enolase and response to initial therapy are important prognostic factors in patients with small cell lung cancer.
    Zhou M; Wang Z; Yao Y; Zhou H; Liu M; Sun J
    Clin Transl Oncol; 2017 Jul; 19(7):865-873. PubMed ID: 28127669
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic implications of neutrophil-to-lymphocyte ratio in patients with extensive-stage small cell lung cancer receiving chemoimmunotherapy: A multicenter, real-world study.
    Bi H; Ren D; Xiao Y; Zhou Y; Yi B; Han W; Shao Y; Wang J; Zhang C; Wang H
    Thorac Cancer; 2024 Mar; 15(7):559-569. PubMed ID: 38294282
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer.
    Tong YS; Tan J; Zhou XL; Song YQ; Song YJ
    J Transl Med; 2017 Oct; 15(1):221. PubMed ID: 29089030
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.